Project Details
Description
A Phase III Randomized, double blind, placebo-controlled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation (STORM)
| Status | Finished |
|---|---|
| Effective start/end date | 5/20/08 → 9/30/14 |
Funding
- BAYER HEALTHCARE PHARMACEUTICALS
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.